Grandad cycling 250 miles for baby loss charity
Kevan Collins, 62, from Diss in Norfolk, embarked on the challenge to raise money for Angels and Rainbows, a Suffolk-based pregnancy and baby loss support group.
Mr Collins set off on Saturday to ride from Diss to London, riding on to Dunwich Beach in Suffolk through the night, and back to Diss.
"I have recently been made a grandfather to young Henry who spent 10 days on life-support, and I dread to think what it would have felt like [to lose him]," he said.
Mr Collins took up cycling during the Covid-19 pandemic.
During the challenge he planned to ride a "normal" 11-speed bike with no power-assistance.
"When I came up with this idea back in February it was to be for an eye charity because I nearly lost my sight," he said, speaking to the BBC while catching a break in Great Dunmow, Essex.
"But, I met up with Angels and Rainbows through friends... and I thought, you know what, I have to do this for them."
The charity, based in Lowestoft, provides counselling and support to those affected by pregnancy or baby loss.
Mr Collins said his goal was to raise £1,500 so those in need of support did not have to face financial barriers during that difficult time.
Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Father takes on walking goal in daughter's memory
Bereavement leave to be extended to miscarriages before 24 weeks
Bereaved dads given support in 'macho' industry
Angels and Rainbows
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Coronary Sinus Reducer Shows Promise, With Caveats
The coronary sinus reducer, an hourglass-shaped stent that narrows the coronary sinus to increase coronary sinus pressure, has shown some promise in treating patients with refractory angina. But a meta-analysis published today in JACC: Cardiovascular Interventions found the benefits of the intervention are likely smaller than those early studies predicted. 'There have been lots of unblinded single-arm studies [of the procedure] but only three randomized controlled trials, so we wanted to look at the different effect sizes to better understand the overall potential efficacy,' said Rasha Al-Lamee, MD, a cardiologist at the National Heart and Lung Institute, part of Imperial College London, London, England, who led the meta-analysis. Al-Lamee and her colleagues looked at data from a combined total of 180 patients in the three trials, as well as 13 single-arm studies with 668 total patients. They found the coronary sinus procedure to be safe, with a success rate of 98.3%. But while both the single-arm and the controlled trials demonstrated improvements in symptoms of angina, the effect size was much smaller in the controlled trials. In the more rigorous trials, 26% of patients experienced at least a one-class improvement and 17% had at least a two-class improvement on the Canadian Cardiovascular Society classification of angina. Those figures were about one third of the gains reported in the single-arm trials. What's more, the randomized controlled trials found no evidence of benefit based on continuous measurements such as the Seattle Angina Questionnaire. Nor did they find improvements in objective measures such as myocardial perfusion associated with the intervention. Deepak Bhatt, MD, a cardiologist at the Icahn School of Medicine at Mount Sinai in New York City, who co-wrote an editorial accompanying the journal article, said more treatment options are needed for patients with refractory angina, who have often exhausted all other medical therapies and surgical procedures. But while coronary sinus reduction shows promise, the meta-analysis demonstrates why more, and larger, trials will be needed before clinicians can use it more broadly. 'It's not an inexpensive procedure, so we want substantial, objectively quantified evidence that it helps patients,' he told Medscape Medical News . 'History is littered with examples of things we were convinced worked but really didn't.' Percutaneous laser therapy, for example, seemed to show benefits for refractory angina at first, but more rigorous randomized trials found no benefit from the procedure, he said. The coronary sinus reducer device is already approved in the UK and Europe and its use is on the rise there, said Al-Lamee, but it has not yet been approved in the US. The ongoing COSIRA-II trial, with an estimated enrollment of 380 patients, should be well-powered enough to provide definitive results and support US approval, she said. Should COSIRA-II show definite benefit, she added, the device may become more of a frontline treatment, used before riskier revascularization options. 'Why have a redo of coronary artery bypass surgery if you have a device that is safe and effective?' she said. Al-Lamee had received consulting and speaker fees from Shockwave Medical, which makes the CSR device. Bhatt reported no relevant financial conflicts.
Fox News
4 hours ago
- Fox News
Just 5 grams of extra fiber per day can make a big difference, expert says
Over 90% of us need more fiber, says Dr. Timothy Spector, a leading microbiome researcher and scientific co-founder of ZOE. He shares how more fiber and better carbs can improve our health.
Yahoo
8 hours ago
- Yahoo
As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?
By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profile telehealth company continues to sell compounded versions of Wegovy at lower prices, testing the limits of federal restrictions on such copies and contributing to weaker sales growth for Novo. In June, Novo accused Hims of violating its intellectual property and endangering patients, scrapping a brief arrangement enabling them to sell Wegovy directly to consumers and raising expectations of litigation. A Novo spokesperson said the Danish drugmaker was not ruling out further legal action after announcing new lawsuits against 14 small pharmacies, telehealth providers and weight-loss clinics this week, but declined to comment on Hims. The drugmaker has filed more than 130 cases in 40 U.S. states. A spokesperson for Hims defended personalization of medicines as the future of healthcare, saying patients and providers use their platform to make clinical decisions. "Investors are happy to see Novo getting more aggressive on the litigation front, but remain puzzled as to why they haven't confirmed that they are filing or have filed litigation against Hims yet," said Barclays analyst Emily Field. Legal experts say Novo's expanding litigation against smaller telehealth players could add pressure on a company like Hims to negotiate a settlement or help the drugmaker test out strategies. At the same time, the fact that Novo and Hims had a prior collaboration may complicate legal action. "Business happens in the shadow of the law," said Robin Feldman, a professor at UC Law San Francisco who has written books on the pharmaceutical industry and its intellectual property battles. "Sometimes companies file against smaller players as a shot across the bow, a way to rattle the larger players." The U.S. Food and Drug Administration set a May 22 deadline for compounding pharmacies to cease mass-producing copies of Wegovy, a practice allowed only when a drug is in shortage. Hims says it still offers personalized versions of Wegovy, in doses not manufactured by Novo, that better suit individual patient needs. The telehealth provider argues that individualized dosing remains legal under compounding rules. Compounding laws 'are just vague enough to allow for different interpretations, and the interpretation that matters – that of the courts – has not been provided to our knowledge,' said TD Cowen analyst Michael Nedelcovych. Novo's cases against smaller compounders could shape how courts interpret those boundaries, said Gaston Kroub, a partner at patent litigation firm Kroub, Silbersher & Kolmykov. 'This is an untested set of affairs,' said Kroub. 'If you want to train for a heavyweight championship fight, you start sparring with lighter opponents.' In addition to trademark infringement, Novo has accused pharmacies of steering people toward compounded Wegovy by interfering with the relationship between clinicians and patients. Josh Gerben, an intellectual property attorney, said the fact that Hims and Novo had a prior business relationship will complicate any claim Novo could bring. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
